Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
August 04 2020 - 6:05AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the
“Company”) today announced that Peter Greenleaf, President and
Chief Executive Officer of Aurinia, will participate in a fireside
chat at the BTIG Virtual Biotechnology Conference on Monday, August
10, 2020 at 11:00 a.m. EDT.
In order to participate in the audio webcast, interested parties
can access the live webcast under "News/Events” through the
“Investors” section of the Aurinia corporate website at
www.auriniapharma.com. A replay of the webcast will be available on
Aurinia’s website.
ABOUT AURINIA
Aurinia Pharmaceuticals is a late-stage clinical
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are impacted
by serious diseases with a high unmet medical need. The Company is
currently seeking FDA approval of voclosporin for the potential
treatment of lupus nephritis (Anticipated PDUFA date: January 22,
2021) and evaluating voclosporin ophthalmic solution (VOS) in a
Phase 2/3 study for the treatment of dry eye syndrome. The
Company’s head office is in Victoria, British Columbia, its U.S.
commercial hub in Rockville, Maryland, and focuses its development
efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200804005227/en/
Investor & Corporate Contact: Glenn Schulman, PharmD,
MPH SVP, Corporate Communications & IR
gschulman@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024